Literature DB >> 28739710

Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer.

Shinkichi Takamori1, Gouji Toyokawa2, Isamu Okamoto3, Kazuki Takada1,4, Yuka Kozuma1, Taichi Matsubara1, Naoki Haratake1, Takaki Akamine1, Masakazu Katsura1, Nobutaka Mukae5, Fumihiro Shoji1, Tatsuro Okamoto1, Yoshinao Oda4, Toru Iwaki6, Koji Iihara5, Yoichi Nakanishi3, Yoshihiko Maehara1.   

Abstract

AIM: To investigate the discordance in the programmed cell death-ligand 1 (PD-L1) expression between primary and metastatic tumors and analyze the association between the discordance and the clinical factors in non-small cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: Twenty-one NSCLC patients who underwent surgery or biopsy for paired primary and metastatic lesions at our Institution from 2005 to 2016 were analyzed. Lesions with the PD-L1 expression being ≥5% were considered PD-L1-positive.
RESULTS: The metastatic sites included the brain (n=16), adrenal gland (n=3), spleen (n=1) and jejunum (n=1). Negative conversion of the primary PD-L1-positive NSCLC and positive conversion of the primary PD-L1-negative NSCLC were observed in 3 (14%) and 2 (10%) cases, respectively. Radiotherapy for the metastatic brain lesion before its resection showed a significant relationship with the positive conversion of the primary PD-L1-negative NSCLC (p=0.048).
CONCLUSION: Radiotherapy-derived effects may contribute to the positive conversion of the primary PD-L1-negative NSCLC. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Programmed cell death-ligand 1; immunotherapy; non-small cell lung cancer

Mesh:

Substances:

Year:  2017        PMID: 28739710     DOI: 10.21873/anticanres.11813

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  14 in total

1.  Radiation Plus Anti-PD-1 Therapy for NSCLC Brain Metastases: A Retrospective Study.

Authors:  Guixiang Liao; Yuting Qian; Sumbal Arooj; Zhihong Zhao; Maosheng Yan; Zihuang Li; Hongli Yang; Tao Zheng; Gang Li; Xianming Li; Muhammad Khan
Journal:  Front Oncol       Date:  2021-10-21       Impact factor: 6.244

2.  Heterogeneity of programmed death-ligand 1 expression and infiltrating lymphocytes in paired resected primary and metastatic non-small cell lung cancer.

Authors:  Jianghua Wu; Wei Sun; Xin Yang; Haiyue Wang; Xinying Liu; Kaiwen Chi; Lixin Zhou; Xiaozheng Huang; Luning Mao; Shuai Zhao; Tingting Ding; Bin Meng; Dongmei Lin
Journal:  Mod Pathol       Date:  2021-09-07       Impact factor: 7.842

3.  An integrated biomarker of PD-L1 expression and intraepithelial CD8+ T cell infiltration was associated with the prognosis of lung cancer patients after intracranial resection of brain metastases.

Authors:  Lin-Lin Li; De-Xiang Zhou; Ming Lu; Dong Zhou; Xiao-Feng Lin; Yu Chen; Kai Yin; Hui-Bo Feng; Wei-Bang Guo; Zhi Xie; Wen-Qing Yan; Zhi-Yi Lv; Dan-Xia Lu; Shui-Lian Zhang; Xu-Chao Zhang
Journal:  Thorac Cancer       Date:  2022-05-20       Impact factor: 3.223

4.  Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study.

Authors:  Kazuki Takada; Gouji Toyokawa; Koichi Azuma; Shinkichi Takamori; Tomoko Jogo; Fumihiko Hirai; Tetsuzo Tagawa; Akihiko Kawahara; Jun Akiba; Isamu Okamoto; Yoichi Nakanishi; Yoshinao Oda; Tomoaki Hoshino; Yoshihiko Maehara
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

Review 5.  Emerging principles of brain immunology and immune checkpoint blockade in brain metastases.

Authors:  Jawad Fares; Ilya Ulasov; Peter Timashev; Maciej S Lesniak
Journal:  Brain       Date:  2021-05-07       Impact factor: 13.501

Review 6.  PD-L1 expression testing in non-small cell lung cancer.

Authors:  Cristina Teixidó; Noelia Vilariño; Roxana Reyes; Noemí Reguart
Journal:  Ther Adv Med Oncol       Date:  2018-04-11       Impact factor: 8.168

Review 7.  [Research Progress of Immunotherapy for Brain Metastases in Patients 
with Drive Gene Negative NSCLC].

Authors:  Shuang Zhang; Jingjing Liu; Changliang Yang; Shuang Li; Ying Cheng
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-08-20

Review 8.  PD-L1 Testing in Cytological Non-Small Cell Lung Cancer Specimens: A Comparison with Biopsies and Review of the Literature.

Authors:  Mohammed S I Mansour; Kajsa Ericson Lindquist; Tomas Seidal; Ulrich Mager; Rikard Mohlin; Lena Tran; Kim Hejny; Benjamin Holmgren; Despoina Violidaki; Katalin Dobra; Annika Dejmek; Maria Planck; Hans Brunnström
Journal:  Acta Cytol       Date:  2021-07-07       Impact factor: 2.319

Review 9.  Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.

Authors:  William J Kelly; Neil J Shah; Deepa S Subramaniam
Journal:  Front Oncol       Date:  2018-07-03       Impact factor: 6.244

10.  Programmed Death-ligand 1 Expression With Clone 22C3 in Non-small Cell Lung Cancer: A Single Institution Experience.

Authors:  Maiko Takeda; Takahiko Kasai; Maiko Naito; Akihiro Tamiya; Yoshihiko Taniguchi; Nobuhiko Saijo; Yoko Naoki; Kyoichi Okishio; Shigeki Shimizu; Kensuke Kojima; Akihiro Nagoya; Tetsuki Sakamoto; Tomoki Utsumi; Hyung-Eun Yoon; Akihide Matsumura; Shinji Atagi
Journal:  Clin Med Insights Oncol       Date:  2019-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.